Vise Technologies Inc. Buys Shares of 6,646 Enovis Corporation $ENOV

Vise Technologies Inc. purchased a new position in Enovis Corporation (NYSE:ENOV) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 6,646 shares of the company’s stock, valued at approximately $208,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. CWM LLC raised its stake in Enovis by 564.9% during the second quarter. CWM LLC now owns 3,790 shares of the company’s stock worth $119,000 after acquiring an additional 3,220 shares during the period. McIlrath & Eck LLC grew its holdings in shares of Enovis by 52.2% during the first quarter. McIlrath & Eck LLC now owns 5,274 shares of the company’s stock valued at $202,000 after purchasing an additional 1,808 shares during the last quarter. Humankind Investments LLC raised its position in shares of Enovis by 8.6% during the 1st quarter. Humankind Investments LLC now owns 5,688 shares of the company’s stock worth $217,000 after purchasing an additional 452 shares during the period. Empowered Funds LLC lifted its holdings in shares of Enovis by 13.0% in the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after purchasing an additional 749 shares during the last quarter. Finally, Quarry LP lifted its holdings in shares of Enovis by 649.2% in the 1st quarter. Quarry LP now owns 6,720 shares of the company’s stock worth $257,000 after purchasing an additional 5,823 shares during the last quarter. 98.45% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ENOV. Weiss Ratings restated a “sell (d-)” rating on shares of Enovis in a research note on Wednesday, October 8th. Wells Fargo & Company upped their price target on shares of Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Needham & Company LLC dropped their price objective on shares of Enovis from $57.00 to $49.00 and set a “buy” rating on the stock in a report on Thursday, August 7th. Canaccord Genuity Group reduced their target price on shares of Enovis from $70.00 to $58.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Finally, UBS Group decreased their target price on shares of Enovis from $65.00 to $57.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Enovis presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.17.

Insider Activity at Enovis

In other news, SVP Bradley J. Tandy purchased 3,200 shares of the stock in a transaction dated Friday, August 22nd. The shares were bought at an average cost of $31.41 per share, for a total transaction of $100,512.00. Following the transaction, the senior vice president owned 43,515 shares in the company, valued at $1,366,806.15. This trade represents a 7.94% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Damien Mcdonald acquired 6,457 shares of the company’s stock in a transaction dated Thursday, September 11th. The stock was purchased at an average cost of $30.97 per share, for a total transaction of $199,973.29. Following the purchase, the chief executive officer directly owned 102,753 shares in the company, valued at approximately $3,182,260.41. This represents a 6.71% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 2.70% of the stock is owned by insiders.

Enovis Stock Performance

ENOV stock opened at $28.31 on Wednesday. The company has a market capitalization of $1.62 billion, a P/E ratio of -1.99 and a beta of 1.67. The company has a 50-day simple moving average of $31.17 and a 200 day simple moving average of $31.21. Enovis Corporation has a fifty-two week low of $25.47 and a fifty-two week high of $49.75. The company has a quick ratio of 1.15, a current ratio of 2.25 and a debt-to-equity ratio of 0.53.

Enovis (NYSE:ENOV) last released its earnings results on Monday, January 8th. The company reported $0.59 EPS for the quarter. Enovis had a negative net margin of 37.80% and a positive return on equity of 6.78%. The firm had revenue of $383.81 million for the quarter. Sell-side analysts predict that Enovis Corporation will post 2.79 earnings per share for the current fiscal year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.